The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Liquid biopsy accelerates genotyping & reduces costs in advanced NSCLC: findings from the PLAN study
David O’Reilly, MBBCh, BAO, MSc, MRCPI, Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland, discusses the findings of a The PLAN Study (NCT05542485), a prospective clinical trial on liquid biopsy in advanced non-small cell lung cancer (NSCLC). Conducted across four cancer centers in Ireland, the study showed that liquid biopsy reduced the time to genotyping results by three weeks, with a median turnaround time of just eight days. A micro-costing analysis revealed that liquid biopsy was significantly more cost-effective than tissue biopsy, highlighting its potential to improve efficiency and reduce unnecessary procedures. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
